Device Trial Radar · NCT07681024
Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
May 1, 2030
Study completion May 1, 2030
Sponsor
- Lead sponsor
- DexCom, Inc.Public (DXCM)
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Global Registry study
Conditions
- Diabetes
Interventions
Dexcom CGM (Continuous Glucose Monitor)Device
Use Dexcom CGM according to approved commercial use. Evaluate HbA1c over time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- EvaluationsTime frame: Up to 8 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.